Xiaojun Zhang

Xiaojun Zhang

Auto-generated profile, based on publicly available information

Xiaojun Zhang

Department of Radiotherapy and Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
XZXiaojun Zhang
Xiaojun Zhang
MGMengxuan Gu
Mengxuan Gu
JZJiahao Zhu
Jiahao Zhu
RGRuike Gu
Ruike Gu
BYBo Yang
Bo Yang
KGKe Gu
Ke Gu
This study aimed to investigate the prognostic value of the Naples Prognostic Score (NPS) in patients with locally advanced cervical cancer (LACC) who received curative concurrent chemoradiotherapy (CCRT). Clinicopathological data from 213 (training set) and 106 (validation set) LACC cases undergoing CCRT were retrospectively analyzed. The receiver operating characteristic curve (ROC) was used to compare the predictive ability of NPS and other indicators for survival. Cox proportional hazard regression was conducted for overall survival (OS) and progression-free survival (PFS). A prediction model using a nomogram was developed with independent prognostic factors in the training set and validated in the validation set. The 5-year OS for the NPS = 1, 2, and 3 groups was 56.8%, 45.4%, and 28.9% (P < 0.001), and the 5-year PFS for the NPS = 1, 2, and 3 groups was 44.9%, 36.7%, and 28.4% (P = 0.001), respectively. NPS showed better predictive ability for OS and PFS compared to other indicators. Multivariate regression analysis identified NPS as an independent prognostic factor for OS (P < 0.001) and PFS (P < 0.001). A predictive nomogram based on NPS was established and validated. The C-indices of the nomogram in the training set were 0.722 for OS and 0.683 for PFS, while in the validation set the C-indices were 0.731 for OS and 0.693 for PFS. This study confirmed that preoperative NPS could serve as a useful independent prognostic factor in LACC patients treated with CCRT.

10 March 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
XZXiaojun Zhang
Xiaojun Zhang
YYYilin Yin
Yilin Yin
TYTiantian Yang
Tiantian Yang
YCYawen Cong
Yawen Cong
SJShengjun Ji
Shengjun Ji
YKYan Kong
Yan Kong
Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) show substantial heterogeneity in survival outcomes, whereas the comparative prognostic value of systemic inflammatory and nutritional biomarkers remains unclear. This study aimed to compare pretreatment inflammatory biomarkers, identify the most informative prognostic indicator, and develop a practical risk-stratification model for LACC. In this multicenter retrospective study, 290 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB–IIIC cervical squamous cell carcinoma treated with definitive platinum-based CCRT followed by brachytherapy at two tertiary centers were analyzed. Twelve pretreatment inflammatory and nutritional indices, including the hemoglobin–albumin–lymphocyte–platelet (HALP) score, pan-immune-inflammation value (PIV), and neutrophil-to-lymphocyte ratio (NLR), were evaluated for overall survival (OS) and progression-free survival (PFS) using the concordance index (C-index), time-dependent area under the curve (AUC), and Brier score. Cox regression identified independent prognostic factors, and HALP-based nomograms were internally validated. Among all biomarkers, HALP showed the best and most stable prognostic performance for both OS and PFS, with the highest discrimination and lowest prediction error. Low HALP remained independently associated with worse OS and PFS in multivariable analysis (OS: hazard ratio [HR], 1.654; 95% confidence interval [CI], 1.165–2.366; PFS: HR, 1.702; 95% CI, 1.233–2.344). Nomograms integrating HALP, tumor size, and human papillomavirus (HPV) status showed good calibration and improved predictive accuracy beyond FIGO stage and the baseline clinical model. HALP may therefore serve as a robust, inexpensive, and clinically accessible biomarker for individualized risk stratification in LACC.